娄华勇,傅建,潘卫东
LOU Huayong,FU Jian,PAN Weidong

• 1:贵州省天然产物研究中心
• 2:贵州医科大学省部共建药用植物功效与利用国家重点实验室
• 3:贵州中医药大学药学院

摘要(Abstract)：

本文回顾性总结了潘卫东研究员项目团队有关二磷酸尿苷-半乳糖变异酶(UGM)探针设计、新型抑制剂的开发及新型筛选技术等方面的研究成果，明确了UGM反应机理，系统构建了贵州特色药用植物的抗结核分枝杆菌天然小分子化合物库，并从中发现了天然产物来源的UGM抑制剂，从而突破了当前UGM抑制剂成药性不佳的瓶颈，证实UGM存在变构位点，为贵州中药民族药的资源开发拓展了新思路。
Objective The study presents a systematic review concerning a novel anti-tubercolosis agents targeting UDP-Galactopyranose mutase(UGM) by Professor Weidong Pan's team from Guizhou China and Chinese academy of sciences, which achieved some original research results based on UGM for probe design, new inhibitor development and novel screening techniques: including the confirmation of the mechanism of UGM reaction, systematical construction of anti-tuberculosis natural products sources from medicinal plants of Guizhou and helpful resources for further research and development of new UGM inhibitor drugs. Moreover, some key scientific problems on UGM research were solved, which confirmed the existence of allosteric sites in UGM. The research results greatly promoted the development of related fields and expanded new conception for the resource development of traditional Chinese medicine and ethnic medicine in Guizhou China.

关键词(KeyWords)： 结核分枝杆菌;二磷酸尿苷-半乳糖变异酶;药用植物;抑制剂;结构修饰;先导化合物
Mycobacterium tuberculosis;uridine diphosphate galactopyranose mutase;medicinal plant;inhibitor;structural modification;lead compound

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(32060100,81903517);; 贵州省科技厅项目(黔科合基础-ZK[2021]534);; 贵阳市高层次创新型青年科技人才(筑科合同[2021]43-10)

作者(Author): 娄华勇,傅建,潘卫东
LOU Huayong,FU Jian,PAN Weidong

DOI: 10.19367/j.cnki.2096-8388.2023.06.001

参考文献(References)：

• [1] 舒薇，孙玙贤，张立杰，等.结核病的研究与创新——2021年世界卫生组织全球结核病报告解读[J].中国防痨杂志，2022,44(1):45-48.
• [2] KIRBY T.Global tuberculosis progress reversed by COVID-19 pandemic[J].Lancet Respiratory Medicine,2021,9(12):e118-e119.
• [3] ADEPOJU P.Tuberculosis and HIV responses threatened by COVID-19[J].Lancet HIV,2020,7(5):e319-e320.
• [4] 朱子豪，张文轩，李天磊，等.抗结核药物研究进展[J].药学学报，2022,57(4):892-902.
• [5] SWINDELLS S,RAMCHANDANI R,GUPTA A,et al.One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis [J].New England Journal of Medicine,2019,380 (11):1001-1011.
• [6] SINGH V,CHIBALE K.Strategies to combat multi-drug resistance in tuberculosis [J].Accounts of Chemical Research,2021,54 (10):2361-2376.
• [7] 屈孟锦，梁正敏，王元智，等.结核分枝杆菌糖代谢的研究进展[J].中国防痨杂志，2020,42(8):874-879.
• [8] WINTON V J,ALDRICH C,KIESSLING L L.Carboxylate surrogates enhance the antimycobacterial activity of UDP-galactopyranose mutase probes[J].ACS Infectious Diseases,2016,2 (8):538-543.
• [9] PELTIER P,BELANOVA M,DIANISKOVA P,et al.Synthetic UDP-furanoses as potent inhibitors of mycobacterial galactan biogenesis[J].Chemistry & Biology,2010,17 (12):1356-1366.
• [10]WINTON V J,JUSTEN A M,DENG H,et al.Deleterious consequences of UDP-galactopyranose mutase inhibition for Nematodes[J].ACS Chemical Biology,2017,12 (9):2354-2361.
• [11]TANNER J J,BOECHI L,ANDREW MCCAMMON J,et al.Structure,mechanism,and dynamics of UDP-galactopyranose mutase[J].Arch Biochem Biophys,2014,544:128-141.
• [12]AHMED D M,CHEM J M,SANDERS D R.Pyrazole and triazole derivatives as mycobacterium tuberculosis UDP-Galactopyranose Inhibitors[J].Pharmaceuticals,2022,15 (2):197.
• [13]WINTON V J,JUSTEN A M,DENG H,et al.Deleterious consequences of UDP-galactopyranose mutase inhibition for nematodes[J].ACS Chemical Biology,2017,12 (9):2354-2361.
• [14]MAALIKI C,FU J,VILLAUME S,et al.Synthesis and evaluation of heterocycle structures as potential inhibitors of Mycobacterium tuberculosis UGM[J].Bioorganic & Medicinal Chemistry,2022,28 (13):115579.
• [15]MARTIN J S,LEVI M E,VOGELAAR N J,et al.Identification of aspergillus fumigatus UDP-galactopyranose mutase inhibitors[J].Scientific Reports,2017,7:10836.
• [16]PAN W D,ANSIAUX C,VINCENT S P.Synthesis of acyclic galactitol-and lyxitol-aminophosphonates as inhibitors of UDP-galactopyranose mutase[J].Tetrahedron Letters,2007,48 (25):4353-4356.
• [17]VANDENBUSSCHE S,DIAZ D,FERNANDEZ-ALONSO M C,et al.Aromatic-carbohydrate interactions:an NMR and computational study of model systems[J].Chemistry-A European Journal,2008,14 (25):7570-7578.
• [18]FREDERIC C J,TIKAD A,FU J,et al.Synthesis of unprecedented sulfonylated phosphono-exo-glycals designed as inhibitors of the three mycobacterial galactofuranose processing enzymes[J].Chemistry-A European Journal,2016,22 (44):15913-15920.
• [19]LOU H Y,ZHENG S,LI T L,et al.Vulgarisin A,a new diterpenoid with a rare 5/6/4/5 ring skeleton from the Chinese medicinal plant Prunella vulgaris[J].Organic Letters,2014,16 (10):2696-2699.
• [20]LOU H Y,JIN L,HAUNG T,et al.Vulgarisins B-D,three novel diterpenoids with a rare skeleton isolated from Prunella vulgaris[J].Tetrahedron Letters,2017,58 (5):401-404.
• [21]MA M F,DENG Q F,LOU H Y,et al.Vulgarisin-type diterpenoids from self-heal (Prunella vulgaris) and their neuroprotective effects against ischemia/reperfusion (I/R) via a mitochondria-related pathway[J].Food Function,2022,13:7062-7074.
• [22]MA F W,LOU H Y,GE Y H,et al.Non-targeted analysis of vulgarisins by using collisional dissociation mass spectrometry for the discovery of analogues from Prunella vulgaris[J].Analytical and Bioanalytical Chemistry,2021,413:6513-6521.
• [23]LOU H Y,YAO J N,PAN J,et al.C21 steroidal glycosides from Prunella vulgaris[J].Journal of Carbohydrate Chemistry,2015,34:358-364.
• [24]LOU H Y,LIU H F,WANG H,et al.Diverse flavonoids from the roots of Indigofera stachyodes[J].Chemistry Biodiversity,2022,19 (10):e202200676.
• [25]LOU H Y,YI P,LIU H F,et al.Novel flavonolignans from the roots of Indigofera stachyodes[J].Fitoterapia,2022,160:105217.
• [26]LIU S L,ZHANG M,BAO Y J,et al.Characterization of a highly selective 2-O-Galactosyltransferase from Trollius chinensis and structure-guided engineering for improving UDP-Glucose selectivity[J].Organic Letters,2021,23:9020-9024.
• [27]VILLAUME S A,FU J,N'GO I,et al.Natural and synthetic flavonoids as potent Mycobacterium tuberculosis UGM inhibitors[J].Chemistry-A European Journal,2017,23 (43):10423-10429.
• [28]FU J,FU H,XIA Y,et al.Identification of inhibitors of UDP-galactopyranose mutase via combinatorial in situ screening[J].Organic & Biomolecular Chemistry,2021,19 (8):1818-1826.
• [29]FU J,HE Z,FU H,et al.Synthesis and evaluation of inhibitors of Mycobacterium tuberculosis UGM using bioisosteric replacement[J].Bioorganic & Medicinal Chemistry,2022,69:116896.
• [30]王青青，傅建，何梓瑶，等.基于 UDP-半乳糖变异酶靶标的肉桂酰氨基酸衍生物的合成及生物活性[J].化学通报，2023,86(2):216-221.
• [31]CARBAJO D,PEREZ Y,GUERRA-REBOLLO M,et al.Dynamic combinatorial optimization of in vitro and in vivo heparin antidotes[J].Journal of Medicinal Chemistry,2022,65:4865-4877.
• [32]CANAL-MARTIN A,PEREZ-FERNANDEZ R.Protein-directed dynamic combinatorial chemistry:an efficient strategy in drug design[J].ACS Omega,2020,5 (41):26307-26315.
• [33]BAGNOLINI G,BALBONI B,SCHIPANI F,et al.Identification of RAD51-BRCA2 inhibitors using N-acylhydrazone-based dynamic combinatorial chemistry [J].ACS Medicinal Chemistry Letters,2022,13 (8):1262-1269.
• [34]FU J,FU H,DIEU M,et al.Identification of inhibitors targeting Mycobacterium tuberculosis cell wall biosynthesis via dynamic combinatorial chemistry[J].Chemical Communications,2017,53 (77):10632-10635.

文章评论(Comment)：